Market research
PLX Protalix BioTherapeutics, Inc
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 194M
- P/E ratio
- 10.48
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.01
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74365A3095
- Market cap
- 194M
- P/E ratio
- 10.48
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.01
About
About Protalix BioTherapeutics, Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PLX discussion.
5 years, 4 months ago
Protalix BioTherapeutics, Inc is currently in a long term downtrend where the price is trading 55.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
Protalix BioTherapeutics, Inc's total revenue rose by 9.8% to $19M since the same quarter in the previous year.
Its net income has dropped by 97.6% to $7K since the same quarter in the previous year.
Finally, its free cash flow fell by 110.6% to $-8M since the same quarter in the previous year.
Based on the above factors, Protalix BioTherapeutics, Inc gets an overall score of 2/5.